Dan L Duncan Cancer Center renewed as NCI designated center
Example of collaborative work
"The Duncan Cancer Center is a great example of collaborative work both within Baylor and with our affiliated teaching hospitals," said Dr. Paul Klotman, BCM president and CEO. "The outstanding team of researchers led by Dr. Kent Osborne is making great advances in translational research – moving lab discoveries to patient care as quickly as possibly."
NCI-designated cancer centers must be exceptional sources of discovery and development of more effective approaches to cancer prevention, diagnosis, and treatment. They also deliver medical advances to patients and their families, educate health care professionals and the public, and reach out to underserved populations.
To continue operating as a NCI-designated cancer center, the Duncan Cancer Center team participated in a nationally-competitive, peer-review process, which evaluated the depth, quality and integration of its efforts to translate laboratory discoveries to clinical care and disseminate new knowledge through outreach and education to the local and regional community.
Particular strengths were noted in the cell and gene therapy, nuclear receptor, breast and pediatric programs. The review also encompassed an evaluation of scientific shared resources which enable investigators and programs to do amazing work.
"The very favorable review of these resources reflects the substantial investment in technology and people that BCM and its partners have made in the research enterprise," said Dr. C. Kent Osborne, director of the Duncan Cancer Center.
Clinical partners of the Duncan Cancer Center include the Texas Children's Cancer Center at Texas Children's Hospital, the Harris County Hospital District's Ben Taub General Hospital and the Michael E. DeBakey VA Medical Center.
As part of the renewal, the Duncan Cancer Center will receive more than $15 million in NCI funding over the next five years.
2nd largest in state
Dan L Duncan Cancer Center investigators have competed effectively to bring approximately $130 million annually in cancer-relevant research funding to Texas, with approximately $44 million coming from the NCI.
It is the second-largest NCI-funded institution in the state. In addition, BCM investigators have been awarded more than $30 million in new awards from the Cancer Prevention and Research Institute of Texas.
Dan L Duncan Cancer Center investigators have much collaboration with their colleagues at the other three NCI-designated cancer centers in Texas. Those include The University of Texas MD Anderson Cancer Center, the Cancer Therapy and Research Center at The University of Texas Health Science Center at San Antonio and most recently (August 2010) the Harold C. Simmons Cancer Center at The University of Texas Southwestern Medical Center in Dallas.
There are 66 NCI-designated cancer centers total in the United States.